Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
- PMID: 29156890
- DOI: 10.21037/cco.2017.10.07
Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous